RALEIGH – Icagen, the Raleigh-based firm focused on small molecule research with potential for use in new drugs, has landed a deal worth as much as $274 million with drug giant Roche.
Icagen recently was sold to San Diego-based Ligan Pharmaceuticials in a $15 million deal.
Icagen and Roche will work on a possible treatment for neurogenerative disease.
“Icagen’s collaboration with Roche was a key value-driver in the acquisition of the Icagen business, and we are very pleased to see this expansion and extension of the relationship,” said John Higgins, Chief Executive Officer of Ligand, in a statement.
“This type of deal fits perfectly within the Ligand strategy to establish and leverage partnerships with global leaders in the industry as they look to access our technology for their drug discovery and development needs. The Icagen team has been a great addition to Ligand’s business.”